Cargando…

Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018

SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common hematological malignancy with median age of diagnosis between 65–70 years. Since the introduction of multiple novel agents in MM management, survival times of MM patients continue to improve. Longer survival in patients with MM may be a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Lv, Chenglan, Zhou, Min, Xu, Jing-Yan, Chen, Bing, Wan, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562683/ https://www.ncbi.nlm.nih.gov/pubmed/36230842 http://dx.doi.org/10.3390/cancers14194919

Ejemplares similares

Primary central nervous system lymphoma in the United States, 1975–2017
por: Lv, Chenglan, et al.
Publicado: (2022)

Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma
por: Wang, Jing, et al.
Publicado: (2023)

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
por: Avivi, Irit, et al.
Publicado: (2023)

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
por: Ailawadhi, S, et al.
Publicado: (2014)

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
por: Razavi, P, et al.
Publicado: (2013)

PB1975: THE RESEARCH ON THE MECHANISM OF RRAD GENE IN MULTIPLE MYELOMA
por: Yi, C., et al.
Publicado: (2022)

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

Risk of multiple myeloma and other malignancies among first‐ and second‐degree relatives of patients with multiple myeloma: A population‐based study
por: Langseth, Øystein O., et al.
Publicado: (2022)

Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
por: Rosenberg, A. S., et al.
Publicado: (2021)

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
por: Ragon, Brittany Knick, et al.
Publicado: (2023)

The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
por: Ipek, Yildiz, et al.
Publicado: (2023)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Multiple myeloma: family history and mortality in second primary cancers
por: Chattopadhyay, Subhayan, et al.
Publicado: (2018)

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries
por: Chen, Tianhui, et al.
Publicado: (2016)

Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan
por: Liu, Yanfang, et al.
Publicado: (2020)

The Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs
por: Pepys, Mark. B.
Publicado: (2018)

Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018
por: Lin, Dongdong, et al.
Publicado: (2021)

Second primary malignancies associated with radiation therapy in cervical cancer patients diagnosed between 1975 and 2011: a population-based competing-risk study
por: Wu, Yijun, et al.
Publicado: (2021)

Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients
por: Miles, Brittany, et al.
Publicado: (2021)

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib
por: Cheng, Qiansong, et al.
Publicado: (2021)

Trends in Epidemiology of Esophageal Cancer in the US, 1975-2018
por: Rodriguez, Gladys M., et al.
Publicado: (2023)

Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma
por: Takano, Junichiro, et al.
Publicado: (2015)

Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
por: Yang, Jay, et al.
Publicado: (2012)

Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018
por: Dinnessen, Manette A. W., et al.
Publicado: (2021)

Epidemiological analysis of second primary malignant neoplasms in cancer survivors aged 85 years and older: a SEER data analysis (1975–2016)
por: Zhao, Xianlan, et al.
Publicado: (2022)

Risk of Second Primary Malignancies Based on the Histological Subtypes of Colorectal Cancer
por: Wu, Meijuan, et al.
Publicado: (2021)

Agenda of the Sixty-Second Meeting at Wednesday, 10 December, 1975
por: Blewett, Myrtle Hildred
Publicado: (1975)

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?
por: Bakanay, Sule Mine, et al.
Publicado: (2012)

Second Primary Conjunctival Squamous Cell Carcinoma on Multiple Myeloma: A Case Report
por: Jo, Woo Gyeong, et al.
Publicado: (2023)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

Second Primary Malignancies in Patients with Colorectal Cancer: A Population‐Based Analysis
por: Jia, Huixun, et al.
Publicado: (2020)

Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients
por: Kotchetkov, Rouslan, et al.
Publicado: (2016)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies
por: Yang, Jing, et al.
Publicado: (2022)

Clinical characteristics and survival of second primary breast carcinoma with extramammary malignancies
por: Jing, Yaoyao, et al.
Publicado: (2023)

Survival analysis of breast cancer patients after diagnosis of second primary malignancies, focusing on the second primary hematologic malignancy
por: Kim, Hyung Jin, et al.
Publicado: (2023)

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
por: Zahnreich, Sebastian, et al.
Publicado: (2021)

Second primary malignancies among cancer patients
por: Zheng, Xuanqi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u4e90papd70k5equk74db2u3j4